Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NSPX Inspyr Therapeutics		$0.00	$0.00 ▼ $0.07	$1.47M	-17.33	13.19 million shs	29.64 million shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A
VAXX Vaxxinity	$0.01 +9,900.0%	$0.01	$0.00 ▼ $0.10	$1.27M	-24.16	6,889 shs	507 shs
VYNE VYNE Therapeutics	$0.32 -3.3%	$0.99	$0.32 ▼ $4.30	$4.90M	1.76	866,382 shs	1.62 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NSPX Inspyr Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%
VAXX Vaxxinity	0.00%	-99.77%	0.00%	-99.00%	-99.50%
VYNE VYNE Therapeutics	-3.20%	-4.17%	-71.29%	-66.70%	-82.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.1724 of 5 stars	3.0	2.0	0.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NSPX Inspyr Therapeutics	0.00	N/A	N/A	N/A
ULUR ULURU	0.00	N/A	N/A	N/A
VAXX Vaxxinity	0.00	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.00	Hold	$6.25	1,840.99% Upside

Current Analyst Ratings Breakdown

Latest NSPX, VAXX, ULUR, and VYNE Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/31/2025	VYNE VYNE Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	VYNE VYNE Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	$0.11 per share	N/A
VYNE VYNE Therapeutics	$476K	10.29	N/A	N/A	$2.56 per share	0.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NSPX Inspyr Therapeutics	-$6.30M	N/A	0.00	N/A	N/A	N/A	N/A	-1,354.49%	N/A
ULUR ULURU	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	-$56.93M	-$0.45	N/A	∞	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	-$39.83M	-$0.90	N/A	N/A	N/A	-8,097.69%	-77.57%	-63.09%	11/6/2025 (Estimated)

Latest NSPX, VAXX, ULUR, and VYNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	VYNE VYNE Therapeutics	-$0.23	-$0.13	+$0.10	-$0.13	$0.15 million	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NSPX Inspyr Therapeutics	N/A	0.09	0.09
ULUR ULURU	N/A	N/A	N/A
VAXX Vaxxinity	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	7.60	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NSPX Inspyr Therapeutics	0.02%
ULUR ULURU	N/A
VAXX Vaxxinity	82.95%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
NSPX Inspyr Therapeutics	0.02%
ULUR ULURU	1.10%
VAXX Vaxxinity	64.06%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NSPX Inspyr Therapeutics	1	543.15 million	N/A	Not Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable
VAXX Vaxxinity	90	126.75 million	45.55 million	Not Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.48 million	Not Optionable

NSPX, VAXX, ULUR, and VYNE Headlines

Recent News About These Companies

VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

August 19 at 6:57 PM | finance.yahoo.com

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 526.7% in July

August 16, 2025 | americanbankingnews.com

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

August 14, 2025 | finance.yahoo.com

VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year

August 14, 2025 | msn.com

VYNE Reports Narrower Loss in Fiscal Q2

August 14, 2025 | aol.comA

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

August 14, 2025 | zacks.com

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

August 14, 2025 | globenewswire.com

VYNE Therapeutics (VYNE) Projected to Post Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

August 5, 2025 | theglobeandmail.com

Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely

August 1, 2025 | finance.yahoo.com

Repibresib gel fails to meet endpoints for nonsegmental vitiligo study

August 1, 2025 | healio.comH

Vyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental Vitiligo

July 31, 2025 | marketwatch.com

VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints

July 31, 2025 | za.investing.com

HC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)

July 31, 2025 | msn.com

VYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary Endpoint

July 31, 2025 | appliedclinicaltrialsonline.comA

VYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint Missed

July 31, 2025 | marketwatch.com

Vyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stock

July 31, 2025 | fiercebiotech.comF

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

July 31, 2025 | msn.com

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

July 30, 2025 | globenewswire.com

Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout

July 28, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPX, VAXX, ULUR, and VYNE Company Descriptions

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

Vaxxinity NASDAQ:VAXX

$0.01 +0.01 (+9,900.00%)

As of 10:11 AM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

VYNE Therapeutics NASDAQ:VYNE

$0.32 -0.01 (-3.30%)

Closing price 03:58 PM Eastern

Extended Trading

$0.32 +0.00 (+0.62%)

As of 04:10 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time